ADAG vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ADAG's Piotroski F-Score of 4/9 indicates weak financial health, with negative profitability and high operating losses, but the company shows strong earnings surprise momentum and improving Q/Q EPS growth. Despite a lack of Altman Z-Score and Graham Number, the stock trades at a premium valuation (Price/Sales: 1886.09) due to high growth expectations in a sector with elevated average revenue growth. Insider sentiment is neutral, and analyst target price suggests significant upside potential. The recent 1-year return of +109.6% and strong quarterly beat rate support a bullish technical and earnings narrative.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ADAG vs LLY: Head-to-Head Comparison
This page compares Adagene Inc. (ADAG) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.